Technetium-99 conjugated with methylene diphosphonate ameliorates ovariectomy-induced osteoporotic phenotype without causing osteonecrosis in the jaw

Calcified Tissue International

Volumn 91, Issue 6, 2012, Pages 400-408

  Zhao, Yinghua ^a   Wang, Lei ^a,c   Liu, Yi ^a   Akiyama, Kentaro ^a   Chen, Chider ^a   Atsuta, Ikiru ^a   Zhou, Tao ^b,c   Duan, Xiaohong ^c   Jin, Yan ^c,d   Shi, Songtao ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b XI'AN JIAOTONG UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^d Engineering Technology Center for Tissue Engineering of Xi'an   (China)

Author keywords

99Tc MDP; Bisphosphonate related osteonecrosis of the jaw; Bone marrow mesenchymal stem cell; Bone mineral density; Ovariectomized mouse

Indexed keywords

DEXAMETHASONE; MEDRONATE TECHNETIUM TC 99M; ZOLEDRONIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE MARROW CELL; BONE MASS; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HISTOLOGY; JAW OSTEONECROSIS; MESENCHYMAL STEM CELL; MICRO-COMPUTED TOMOGRAPHY; MOLAR TOOTH; MORPHOMETRICS; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RISK ASSESSMENT; TH17 CELL; TRABECULAR BONE; WESTERN BLOTTING;

ANIMALS; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; FEMALE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; OSTEOPOROSIS; OVARIECTOMY; PHENOTYPE; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M MEDRONATE;

EID: 84871241628     PISSN: 0171967X     EISSN: 14320827     Source Type: Journal    
DOI: 10.1007/s00223-012-9649-7     Document Type: Article

References (37)

1. Rachner TD, Khosla S, Hofbauer LC (2011) Osteoporosis: now and the future. Lancet 377:1276-1287
2. Cenci S, Weitzmann MN, Roggia C, Namba N, Novack D, Woodring J, Pacifici R (2000) Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Invest 106:1229-1237
3. Schett G, David JP (2010) The multiple faces of autoimmunemediated bone loss. Nat Rev Endocrinol 6:698-706
4. Teitelbaum SL (2004) Postmenopausal osteoporosis, T cells, and immune dysfunction. Proc Natl Acad Sci USA 101:16711-16712
5. Weitzmann MN, Pacifici R (2006) Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest 116:1186-1194
6. KushnerGM, AlpertB(2011)Bisphosphonate-related osteonecrosis of the jaws. Curr Opin Otolaryngol Head Neck Surg 19(4):302-306
7. Kikuiri T, Kim I, Yamaza T et al (2010) Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice. J Bone Miner Res 25:1668-1679
8. Bagan J, Scully C, Sabater V, Jimenez Y (2009) Osteonecrosis of the jaws in patients treated with intravenous bisphosphonates (BRONJ): a concise update. Oral Oncol 45:551-554
9. Lai K, Xu L, Jin C, Wu K, Tian Z, Huang C, Zhong X, Ye H (2011) Technetium-99 conjugated with methylene diphosphonate (99Tc-MDP) inhibits experimental choroidal neovascularization in vivo and VEGF-induced cell migration and tube formation in vitro. Invest Ophthalmol Vis Sci 52:5702-5712
10. Yan SX, Wang Y, Peng GJ, Lu XP, Fu Y (2011) Effects of technetium-99 methylenediphosphonate on cytokine-induced activation of retro-ocular fibroblasts from patients with Graves' ophthalmopathy. Nucl Med Commun 32:142-146
11. Kovacic N, Grcevic D, Katavic V, Lukic IK, Grubisic V, Mihovilovic K, Cvija H, Croucher PI, Marusic A (2010) Fas receptor is required for estrogen deficiency-induced bone loss in mice. Lab Invest 90:402-413
12. Yamaza T, Miura Y, Bi Y et al (2008) Pharmacologic stem cell based intervention as a new approach to osteoporosis treatment in rodents. PLoS ONE 3:2615
13. Daci E, Verstuyf A, Moermans K, Bouillon R, Carmeliet G (2000) Mice lacking the plasminogen activator inhibitor 1 are protected from trabecular bone loss induced by estrogen deficiency. J Bone Miner Res 15:1510-1516
14. Okada Y, Morimoto I, Ura K, Nakano Y, Tanaka Y, Nishida S, Nakamura T, Eto S (1998) Short-term treatment of recombinant murine interleukin-4 rapidly inhibits bone formation in normal and ovariectomized mice. Bone 22:361-365
15. Yamaza T, Ren G, Akiyama K, Chen C, Shi Y, Shi S (2011) Mouse mandible contains distinctive mesenchymal stem cells. J Dent Res 90:317-324
16. Roggia C, Gao Y, Cenci S, Weitzmann MN, Toraldo G, Isaia G, Pacifici R(2001) Upregulation ofTNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci USA 98:13960-13965
17. Miura M, Chen XD, Allen MR et al (2004) A crucial role of caspase-3 in osteogenic differentiation of bone marrow stromal stem cells. J Clin Invest 114:1704-1713
18. Cohen A, Dempster DW, Recker RR et al (2011) Abnormal bone microarchitecture and evidence of osteoblast dysfunction in premenopausal women with idiopathic osteoporosis. J Clin Endocrinol Metab 96(10):3095-3105
19. Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115-1117
20. Marx RE, Sawatari Y, Fortin M, Broumand V (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63:1567-1575
21. Khosla S, Burr D, Cauley J et al (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479-1491
22. Wolf AM, Rumpold H, Tilg H, Gastl G, Gunsilius E, Wolf D (2006) The effect of zoledronic acid on the function and differentiation of myeloid cells. Haematologica 91:1165-1171
23. Fiore F, Castella B, Nuschak B, Bertieri R, Mariani S, Bruno B, Pantaleoni F, Foglietta M, Boccadoro M, Massaia M (2007) Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid. Blood 110:921-927
24. Sonis ST,WatkinsBA, LyngGD,LermanMA,AndersonKC(2009) Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonaterelated osteonecrosis in cancer patients. Oral Oncol 45:164-172
25. Contie S, Voorzanger-Rousselot N, Litvin J, Bonnet N, Ferrari S, Clezardin P, Garnero P (2010) Development of a new ELISA for serum periostin: evaluation of growth-related changes and bisphosphonate treatment in mice. Calcif Tissue Int 87:341-350
26. Yamane H, Sakai A, Mori T, Tanaka S, Moridera K, Nakamura T (2009) The anabolic action of intermittent PTH in combination with cathepsin K inhibitor or alendronate differs depending on the remodeling status in bone in ovariectomized mice. Bone 44:1055-1062
27. Kemp CJ, Leary CN, Drinkwater NR (1989) Promotion of murine hepatocarcinogenesis by testosterone is androgen receptor-dependent but not cell autonomous. Proc Natl Acad Sci USA 86:7505-7509
28. Chang J, Wang Z, Tang E, Fan Z, McCauley L, Franceschi R, Guan K, Krebsbach PH, Wang CY (2009) Inhibition of osteoblastic bone formation by nuclear factor-kappaB. Nat Med 15:682-689
29. EbertR,Zeck S,KrugR,Meissner-Weigl J, SchneiderD, Seefried L, Eulert J, Jakob F (2009) Pulse treatment with zoledronic acid causes sustained commitment of bone marrow derived mesenchymal stem cells for osteogenic differentiation. Bone 44:858-864
30. Duque G, Rivas D (2007) Alendronate has an anabolic effect on bone through the differentiation of mesenchymal stem cells. J Bone Miner Res 22:1603-1611
31. Li YF, Zhou CC, Li JH, Luo E, Zhu SS, Feng G, Hu J (2012) The effects of combined human parathyroid hormone (1-34) and zoledronic acid treatment on fracture healing in osteoporotic rats. Osteoporos Int 23:1463-1474
32. Rizzoli R, Akesson K, Bouxsein M, Kanis JA, Napoli N, Papapoulos S, Reginster JY, Cooper C (2011) Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int 22:373-390
33. Allen MR, Burr DB (2007) Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment. J Bone Miner Res 22:1759-1765
34. Sakaguchi S, Yamaguchi T, Nomura T, Ono M (2008) Regulatory T cells and immune tolerance. Cell 133:775-787
35. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT (2005) Interleukin 17-producing CD4? effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6:1123-1132
36. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441:235-238
37. Awasthi A, Murugaiyan G, Kuchroo VK (2008) Interplay between effector Th17 and regulatory T cells. J Clin Immunol 28:660-670